Key result
Astaxanthin reduces serum OxLDL by ~317 pg/mL versus control in adults with central obesity.
Why the study?
In individuals with obesity, increased LDL oxidation forms oxidized LDL and raises coronary artery disease risk, and this study evaluated the effect of 28-day low-dose astaxanthin supplementation on blood OxLDL levels in central obesity.
Does astaxanthin 4 mg/day for 28 days reduce serum oxidized LDL levels in adults with central obesity?
RCT (n=44)
Open-label
Randomized
No
Does astaxanthin 4 mg/day for 28 days reduce serum oxidized LDL levels in adults with central obesity?
Short-term, low-dose astaxanthin supplementation (4 mg/day for 28 days) significantly reduces serum oxidized LDL levels in adults with central obesity.
Answers are grounded in this paper and cite their sources.
May reduce oxidative markers in central obesity; hypothesis-generating and should not yet change practice.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Mulyamin et al. (2026) conducted an RCT in Central obesity (n=44). Astaxanthin vs. No intervention was evaluated on Serum oxidized low-density lipoprotein (OxLDL) levels at 28 days (pg/mL) (MD 316.88 pg/mL, 95% CI 52.24-581.51, p=0.02). Astaxanthin reduced serum OxLDL levels in adults with central obesity compared to control.
Synapse has enriched 10 related papers. Consider them for comparative context: